GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology.
Our proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), and Emory University. Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa) and Zika virus. We also have initiated programs to develop a vaccine to treat chronic Hepatitis B infection and to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases and we intend to pursue expansion of our product.
We know our work could affect the lives of millions worldwide, and we invite you to join our effort.